March 2025's European Penny Stocks To Watch

As the European markets navigate the complexities of U.S. trade policy uncertainties, recent economic measures by Germany and the European Union have provided some stability amidst volatility. Penny stocks, often overlooked due to their association with smaller or newer companies, continue to offer intriguing potential for investors seeking growth at lower price points. Despite being considered a relic of past market eras, these stocks can still present significant opportunities when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks In Europe

Name	Share Price	Market Cap	Financial Health Rating
Angler Gaming (NGM:ANGL)	SEK3.70	SEK277.44M	★★★★★★
Netgem (ENXTPA:ALNTG)	€0.99	€33.15M	★★★★★★
Hifab Group (OM:HIFA B)	SEK3.98	SEK242.14M	★★★★★★
High (ENXTPA:HCO)	€2.67	€52.44M	★★★★★★
Transferator (NGM:TRAN A)	SEK2.24	SEK210.19M	★★★★★☆
Deceuninck (ENXTBR:DECB)	€2.215	€306.55M	★★★★★★
I.M.D. International Medical Devices (BIT:IMD)	€1.38	€23.9M	★★★★★☆
Bredband2 i Skandinavien (OM:BRE2)	SEK2.08	SEK1.99B	★★★★☆☆
Riber (ENXTPA:ALRIB)	€3.04	€63.7M	★★★★★☆
IMS (WSE:IMS)	PLN3.66	PLN124.05M	★★★★☆☆

Click here to see the full list of 433 stocks from our European Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Horisont Energi (OB:HRGI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Horisont Energi AS is a clean energy company focused on producing and selling clean ammonia and hydrogen in Norway, with a market cap of NOK37.95 million.

Operations: Horisont Energi AS has not reported any revenue segments.

Market Cap: NOK37.95M

Horisont Energi AS, with a market cap of NOK37.95 million, is pre-revenue and currently unprofitable. The company's short-term assets significantly exceed both its short-term and long-term liabilities, indicating a strong liquidity position despite having less than a year of cash runway. Recent board changes include the appointment of Frode Sigurd Berg as Chair, bringing extensive experience in strategic processes. However, the board's average tenure is under one year, suggesting limited experience. The stock has experienced high volatility recently and remains debt-free but faces challenges with declining earnings over five years.

• Click to explore a detailed breakdown of our findings in Horisont Energi's financial health report.
• Assess Horisont Energi's previous results with our detailed historical performance reports.

Isofol Medical (OM:ISOFOL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Isofol Medical AB is a clinical stage biotech company focused on developing, commercializing, and selling oncology drugs in Sweden and internationally, with a market cap of SEK262.95 million.

Operations: Isofol Medical AB has not reported any revenue segments.

Market Cap: SEK262.95M

Isofol Medical AB, with a market cap of SEK262.95 million, is pre-revenue and unprofitable. The company has reduced its losses over the past five years by 27.1% annually, though recent earnings show increased losses compared to last year. Despite high volatility in share price and a new management team with limited experience (1.2 years average tenure), Isofol maintains strong liquidity as short-term assets exceed liabilities significantly, and it remains debt-free with a cash runway of over one year based on current free cash flow trends without significant shareholder dilution recently.

• Unlock comprehensive insights into our analysis of Isofol Medical stock in this financial health report.
• Learn about Isofol Medical's historical performance here.

Medhelp Care Aktiebolag (OM:MEDHLP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Medhelp Care Aktiebolag (publ) is a software-as-a-service company that operates a health platform focused on data-driven corporate health in Sweden and Denmark, with a market cap of SEK104.70 million.

Operations: The company generates SEK91.14 million in revenue from its healthcare software segment.

Market Cap: SEK104.7M

Medhelp Care Aktiebolag has achieved profitability, marking a significant turnaround from previous losses. The company reported a net income of SEK2.12 million for the full year ending December 2024, compared to a net loss of SEK11.01 million the previous year, while maintaining stable revenue at SEK91.14 million. Its financial health is robust with cash exceeding total debt and short-term assets covering both short- and long-term liabilities comfortably. Despite high share price volatility, Medhelp's earnings are forecasted to grow significantly, supported by an experienced management team and board of directors with substantial tenure in their roles.

• Click here and access our complete financial health analysis report to understand the dynamics of Medhelp Care Aktiebolag.
• Gain insights into Medhelp Care Aktiebolag's outlook and expected performance with our report on the company's earnings estimates.

Summing It All Up

• Click this link to deep-dive into the 433 companies within our European Penny Stocks screener.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com